Are you a hematologist or oncologist treating patients with multiple myeloma? If so, this half-day workshop is for you.
The International Myeloma Society is pleased to announce the launch of its half-day Practical Insights in Novel Immune Therapies in Multiple Myeloma being held in convenient locations across the globe in 2022.

The treatment of multiple myeloma has dramatically evolved in recent years with immune-based strategies resulting in a very high impact in the relapsed refractory setting. Several targets are being evaluated, but B cell maturation antigen (BCMA) has proven to result in high response rates with excellent duration of responses in a very heavily pretreated patient population. Given the plethora of different drug products in this space, including antibody-drug conjugates, T cell engagers and CAR T cells, this is a busy landscape and requires specific education around patient characteristics, treatment selection, and toxicity management to provide the best treatment options for our patients.

This high-impact, three-hour educational program seeks to bridge the knowledge gap between CAR T administering centers and smaller community centers where the vast majority of oncology patients are treated, and raise awareness of novel immune based strategies including antibody drug conjugates, bispecific T cell engagers, and CAR T therapies among healthcare professionals.

At the conclusion of this educational activity, you will be able to:
1. Understand the types of patients who should be considered for novel immune based strategies including bispecific T cell engagers and CAR T cell therapy.
2. Understand the differences between TCEs, antibody drug conjugates, and CAR T cell process and data for appropriate care of the patient prior to consideration for these therapies.
3. Understand toxicities and their management post-novel immune strategies.
Upcoming WORKSHOPS
Vienna, Austria (In-Person Only)
Thursday, October 6, 2022
1:00-4:00 PM

Paris, France (In-Person Only)
Thursday, October 13, 2022

East Coast (Virtual)
Wednesday November 2, 2022 6:00-7:30 PM EST

West Coast (Virtual)
Wednesday, November 16, 2022 6:00-7:30 PST
Additional cities to be announced soon.
QUESTIONS?
Schedule
5:30 pm
Registration and Check-In
Arrive, collect your registration badge, and network with fellow participants
6:00 PM
Welcome
Hear opening remarks from the workshop chairs
6:05 PM
Overview of Immune Therapies and CAR T Cells:
Defining the unmet need in relapsed refractory multiple myeloma; MOA of CAR T cells and TCEs
6:20 PM
Targeting BCMA with TCEs and/or CAR T Cell Therapy and clinical results
6:35 PM
Case Study presented by a local Oncologist
6:45 PM
Panel Discussion
7:00 PM
Patients and the Process:
Defining patient selection for TCEs/CAR T cell therapy in practice
Understanding of CAR T eligibility to ensure the right patient is referred for CAR T therapy
7:15 PM
Managing TCE/CAR T Cell Toxicities:
Practical tips for short and long-term adverse events associated with CAR T cell therapy (focus on needs for coordination between community centers and CAR T centers)
7:30 PM
Case Study presented by a local Oncologist
7:40 PM
Panel Discussion
7:55 PM
Future Advances in Immune Therapies and Cellular Therapy
8:15 PM
Managing Relapse Following Novel Immune Therapies
8:35 PM
Case Study presented by a local Oncologist
8:45 PM
Panel Discussion
9:00 PM
Closing Remarks
This is an in-person meeting, seating is limited. Dinner will be served. Registration is complimentary and limited to licensed HCPs only.
The International Myeloma Society gratefully acknowledges the following organizations for their support of the workshop:
Join us at an upcoming workshop in a city near you.
A limited number of seats are available in each location. Reserve your spot today!
About the International Myeloma Society
The International Myeloma Society is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved in the study of myeloma.

The purpose of this society is to promote research, education, clinical studies (including diagnosis and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide.

The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.

Processing Registration...